Abstract
In a recent issue of JAMA, Smith et al. evaluated the use of duloxetine in the treatment of patients with painful chemotherapy-induced peripheral neuropathy (CIPN). Here, JADPRO contributors give an overview of the Smith study and offer a researcher’s perspective on the challenges associated with studying CIPN.
